Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Germany

European Innovation Council · Running

Phactory Final development and commercial preparation of Phactory™, a universal platform technology to enable scalable phagebased drug development and production

Coordinator
Invitris, Germany
Runs
1 July 2025 to 30 June 2027
Status
Running
EU funding
€2.5m
Total cost
—
Partners
1 organisations in 1 countries
Type
European Innovation Council
Grant agreement
101218038

What the project is doing

In the project's own words, from its summary on CORDIS.

The rise of drug-resistant bacteria necessitates the development of alternative therapies that can specifically target and eliminate these pathogens while minimizing harm to the patient's microbiome. Bacteriophages (phages) are potent therapeutics that can fight multidrugresistant pathogenic bacteria. Unlike broad-spectrum antibiotics, phages can selectively eliminate bacteria. However, the current production processes for phages pose considerable biosafety concerns and are often relatively inefficient, unreliable, and unscalable.

Invitris has fundamentally transformed the way phages can be developed with its unique in vitro platform technology, Phactory™. For the first time, Phactory™ enables scalable, personalized production and rapid engineering of novel drugs based on phages. We aim to leverage the support by EIC to standardize the clinical production process of Phactory™ and conduct clinical trials to validate the efficacy and safety of novel phage-based therapies.

Topics

Who is involved

OrganisationCityCountryRole
InvitrisPlanegg-MartinsriedGermanyCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI